About Photonpharma
Photonpharma is a company based in Fort Collins (United States) founded in 2019 by Amanda Guth and Raymond Goodrich. Photonpharma has raised $5.76 million across 3 funding rounds. Photonpharma offers products and services including Innocell. Photonpharma operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
- Headquarter Fort Collins, United States
- Founders Amanda Guth, Raymond Goodrich
- SectorsHealthcare
- Website photonpharmaceuticals.com
- Legal Name Photonpharma Inc
- Total Equity Funding$5.76M (USD)
in 3 rounds
- Latest Funding Round$2.5M (USD), Seed
Aug 2024
Products & Services of Photonpharma
Photonpharma offers a comprehensive portfolio of products and services, including Innocell.
Vaccine for delaying progression of solid tumor cancers in clinical trials.
Funding Insights of Photonpharma
Photonpharma has successfully raised a total of $5.76M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $2.5 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.76M
- Total Rounds 3
- Last Round Seed — $2.5M
- First Round $2.91M
(Aug 2023)
All 3 funding rounds of Photonpharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2024 | $2.5M | Seed | – | – | – |
| May 2024 | $349,998 | Seed | – | – | – |
| Aug 2023 | $2.91M | Seed | – | – | – |
People of Photonpharma
5 people are tracked at Photonpharma (4 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Amanda Guth | Co-Founder & CSO | Leadership |
Raymond Goodrich | Co-Founder | Leadership |
Terry Opgenorth | Independent Board Director and CEO | Leadership |
Milton Chang | Director | Leadership |
David Maranon | Senior Scientist | Team |
Complete people profiles for Photonpharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Photonpharma
3 dated milestones of Photonpharma across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Photonpharma is founded.
- Funding First funding round of $2.9M.
- Funding Latest funding round, Seed, of $2.5M.
Competitors of Photonpharma
Photonpharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| alxoncology.com | 2015 | Burlingame, United States | $123.02M | 59 | ALX Oncology is focused on advancing cancer treatment therapies. | |
| regeneron.com | 1988 | Tarrytown, United States | – | 13,450 | Antibodies are developed for treating cancer, eye, and inflammatory diseases. | |
| ventyxbio.com | 2018 | Encinitas, United States | $165.3M | 79 | Therapeutics for autoimmune diseases are developed by the company. | |
| ascendispharma.com | 2007 | Hellerup, Denmark | $108.7M | 573 | Long-acting prodrug therapies are developed for endocrine and rare diseases. | |
| strandtx.com | 2017 | Cambridge, United States | $103.14M | 47 | mRNA therapeutics platform is provided for multi-functional treatments. |
Detailed competitors of Photonpharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Photonpharma
The website of Photonpharma (photonpharmaceuticals.com) receives about 2.1K visits a month.
- Monthly visits2.1K
Latest news on Photonpharma
Complete news archive for Photonpharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Photonpharma
10 companies that operate in the same segment as Photonpharma (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Photonpharma
Photonpharma was founded in 2019 and raised its 1st funding round 4 years after it was founded.
Photonpharma is headquartered in Fort Collins, United States. It is registered at Fort Collins, Colorado, United States.
Photonpharma is a funded company, having raised a total of $5.76M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.91M, raised on Aug 2023.
Photonpharma was founded in 2019 and is based in Fort Collins, United States. Operations focus on biotechnology within the immunotherapy sector. Antigen presentation technology is developed to deliver personalized same-day treatments for solid and liquid tumors. The Innocell product utilizes live, replication-inactivated tumor cells for autologous inoculation on the same day. Tumor cells are fully inactivated, and an immune response is triggered as a result.
Photonpharma's top competitors include Moderna, BeiGene and Strand Therapeutics.
Photonpharma offers Innocell.
Photonpharma operates through Photonpharma Inc.